Continuous Bioprocessing Market Global Report 2026

The continuous bioprocessing market size has grown exponentially in recent years. It will grow from $0.38 billion in 2025 to $0.46 billion in 2026 at a compound annual growth rate (CAGR) of 21.9%. The growth in the historic period can be attributed to growth in biologics manufacturing demand, increasing adoption of biopharmaceutical production technologies, expansion of monoclonal antibody production, rising investments in biotechnology research activities, increasing focus on reducing manufacturing costs.

The continuous bioprocessing market size is expected to see exponential growth in the next few years. It will grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 21.5%. The growth in the forecast period can be attributed to growing demand for cell and gene therapies, increasing investments in advanced bioprocessing facilities, rising demand for scalable manufacturing platforms, increasing adoption of automated process monitoring systems, expansion of personalized medicine development. Major trends in the forecast period include increasing adoption of single-use processing systems, growing preference for integrated upstream and downstream workflows, rising demand for high-yield biomanufacturing processes, increasing focus on process consistency and quality control, expansion of continuous production methods for biologics manufacturing.

The increasing demand for personalized medicine is expected to propel the growth of the continuous bioprocessing market going forward. Personalized medicine refers to a medical approach that customizes treatment based on an individual's genetic profile, biomarkers, and disease characteristics to improve therapeutic effectiveness and patient outcomes. The increasing demand for personalized medicine is driven by the growing adoption of targeted and precision therapies tailored to individual patient profiles. Continuous bioprocessing supports personalized medicine by enabling flexible, scalable, and efficient production of small-batch, high-value biologics and advanced therapies while improving product consistency and reducing manufacturing timelines. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, representing a significant increase from the six approved in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the continuous bioprocessing market.

Leading companies operating in the continuous bioprocessing market are focusing on developing advanced single-use manufacturing solutions, such as integrated antibody drug conjugate processing platforms, to improve production efficiency, enhance contamination control, and support flexible biologics manufacturing. Integrated antibody drug conjugate processing platforms refer to specialized single-use systems designed to streamline the manufacturing, handling, and purification of antibody drug conjugates in biopharmaceutical production environments. For example, in September 2024, Merck KGaA, a Germany-based science and technology company, launched the Mobius ADC Reactor, a single-use manufacturing solution designed to improve the safe and efficient production of antibody drug conjugates. The system supports high-potency bioprocessing applications by offering enhanced containment, disposable fluid paths, and flexible scalability, helping biopharmaceutical manufacturers optimize production workflows and reduce cross-contamination risks during continuous processing operations.

In August 2024, Merck KGaA, a Germany-based science and technology company, acquired Mirus Bio for $600 million. Through this acquisition, Merck aimed to strengthen its viral vector bioprocessing capabilities and expand its integrated solutions portfolio for cell and gene therapy manufacturing. The acquisition also enhanced Merck’s upstream bioprocessing offerings by incorporating Mirus Bio’s advanced transfection technologies, which are widely used in viral vector production processes. Mirus Bio is a US-based biotechnology company specializing in transfection reagents and gene delivery technologies used in viral vector-based cell and gene therapies.

Major companies operating in the continuous bioprocessing market are Thermo Fisher Scientific Inc.; Danaher Corporation; Merck KGaA; Sartorius AG; Lonza Group AG; Repligen Corporation; 3M Company; Fujifilm Corporation; Asahi Kasei Corporation; Corning Incorporated; Entegris Inc.; Getinge AB; Eppendorf SE; Bio-Rad Laboratories; Meissner Filtration Products Inc.; Shimadzu Corporation; Hamilton Company; Adolf Kühner AG; PBS Biotech Inc.; Esco Lifesciences Group; Bio-Techne; SATAKE MultiMix Corporation.

North America was the largest region in the continuous bioprocessing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the continuous bioprocessing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the continuous bioprocessing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The continuous bioprocessing market includes revenues earned by entities by providing services such as continuous cell culture processing, process optimization, integrated biomanufacturing support, automation and monitoring solutions, and contract manufacturing for biologics production. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The continuous bioprocessing market also includes sales of bioprocess skids, nutrient feed systems, aseptic transfer components, disposable bioprocess containers, inline dilution systems, microbial fermentation equipment, flow distribution manifolds, and integrated fluid handling systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The continuous bioprocessing market research report is one of a series of new reports that provides continuous bioprocessing market statistics, including continuous bioprocessing industry global market size, regional shares, competitors with a continuous bioprocessing market share, detailed continuous bioprocessing market segments, market trends and opportunities, and any further data you may need to thrive in the continuous bioprocessing industry. This continuous bioprocessing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.